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Introduction
Invasive fungal infections shall be considered a major 
healthcare issue. Recent statistics attest that fungi are 
responsible for approximately 20% of all sepsis cases. 
Candida species (especially Candida Albicans and Candida 
Glabrata) are the most common fungal pathogens (~90%), 
whilst Aspergillus and Cryptococcus species are also frequent 
causes of sepsis in immunocompromised patients (1). Like 
all other forms of sepsis, early and accurate diagnosis is hence 
pivotal for establishing a timely and appropriate treatment 
and reversing an otherwise unfavourable outcome (2), since 
mortality can be as high as 80% when the appropriate 
treatment is delayed more than 48 hours from the onset of 
infection (3).
Current diagnostics of invasive fungal infections
The gold standard for diagnosing invasive fungal infection 
is currently represented by conventional mycological 
testing, thus including microscopic examination and/or 
blood culture (2). The first approach has some well-known 
drawbacks. The accuracy of microscopic diagnosis of fungal 
infections varies largely depending on technical skills, 
necessitates the support of skilled laboratory professionals 
for smear examination, does not allow to always accurately 
recognizing the fungal strains, is influenced by source or 
quality of samples and nature of responsible pathogens, and 
is plagued by an obviously low throughput (4). Blood culture 
has also important limitations, such as long turnaround 
time due to slow growth of fungi in culture systems (i.e., 
1–4 days), late positivity, suboptimal diagnostic accuracy 
(often <50%), significant risk of false negative results when 
specimens are collected from patients undergoing treatment 
with antifungal agents, risk of environmental contamination, 
relatively low throughput along with biosafety hazards due 
to culture of mycelial forms (4). Despite the introduction 
of matrix-assisted laser desorption/ionisation time of flight 
mass spectrometry (MALDI TOF-MS) has enabled major 
diagnostic advancements for rapid identification of bacteria 
and yeasts from culture plates, its use in positive blood 
cultures seems still in infancy (5). The major drawbacks 
are represented by potential spectral interference from 
hemoglobin and proteins, which generates identification 
problems and ultimately reduces diagnostic sensitivity, as 
well as by the limited efficiency of current databases and 
software programs for complete identification of non-
bacterial pathogens such as fungi (6).
Serologic testing has emerged as a valuable perspective 
for diagnosing patients with invasive fungal infections, 
since it may offset some limitations of conventional 
mycological testing. Nevertheless, even this approach has 
caveats, such as suboptimal diagnostic accuracy especially 
in immunocompromised patients and in those infected 
by rare fungal species (e.g., fusariosis, mucormycosis and 
scedosporiosis), relatively long turnaround time, modest 
throughput, possible generation of false positive results due 
to physiological colonization or opportunistic infections, 
need of clinical validation of some antigen surrogates of 
infection, whilst results are also strictly dependent on 
antibody type and kinetics (4) (Table 1). 
The assessment of serum 1,3-beta-D-glucan, which 
has recently been proposed as useful screening test for 
diagnosing some invasive fungal infections, has also some 
diagnostic drawbacks, which are especially represented by 
the risk of false-positive reactions (especially in patients 
with bacterial infection or those undergoing dialysis) and 
undecided cut-offs (4). A recent meta-analysis of prospective 
studies also concluded that although the overall diagnostic 
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efficiency of this test was 89% [area under the curve (AUC), 
0.89; 95% confidence interval (CI), 0.86–0.91], slightly 
higher for candidiasis (AUC, 0.88; 95% CI, 0.83–0.98) than 
for aspergillosis (AUC, 0.85; 95% CI, 0.70–0.95) (7), the 
cumulative diagnostic sensitivity was found to be suboptimal 
(i.e., 0.75; 95% CI, 0.63–0.84), thus leaving up to one-
fourth of patients with a risk of remaining non-diagnosed. 
Similar conclusions were recently published by the Third 
European Conference on Infections in Leukemia on the 
use of mannan antigen and anti-mannan antibodies for 
diagnosing invasive candidiasis (8), wherein the diagnostic 
sensitivity of these two biomarkers used alone was only 
0.58 (95% CI, 0.53–0.62) and 0.59 (95% CI, 0.54–0.65), 
respectively, whilst their combined diagnostic sensitivity was 
0.83 (95% CI, 0.79–0.87). Taken together, these findings 
would suggest that negative results of 1,3-beta-D-glucan, 
mannan antigen and anti-mannan antibodies should not 
be used to safely rule out invasive fungal diseases, whilst 
relatively long turnaround time, low throughput and 
limited availability of these tests in clinical laboratories are 
additional well-known drawbacks (Table 1). Overlapping 
conclusions can be drawn for other immunological assays 
such as glucuronoxylomannan and galactomannan (4).
Owing to the inherent drawbacks of conventional 
mycological testing (Table 1), the development of alternative 
approaches would hence be highly advisable. The 
development of rapid and high-throughput molecular biology 
techniques, especially real-time polymerase chain reaction 
(RT-PCR) and Multiplex, shall be seen as one of the most 
important breakthroughs occurred over the past decades. The 
molecular identification of fungal pathogen does not require 
live cells for success and may also enable to specifically design 
primers for achieving a final etiological diagnosis (4). On 
the other hand, some molecular biology techniques are still 
relatively time-consuming (i.e., >6 hours), are not always 
available in clinical laboratories performing urgent testing, 
are highly sensitive to the lysis technique used for extracting 
nucleic acids and to environmental contamination, can 
generate false positive results due to deep-seated infections, 
whilst the selection of optimal sample matrix (i.e., whole 
blood, serum or plasma) along with the limitation and poor 
standardization of test panels can ultimately influence their 
diagnostic performance (9) (Table 1).
The future of fungal sepsis biomarkers
An ideal sepsis biomarker shall allow making early diagnoses 
with high sensitivity and specificity, precisely identifying 
the pathogen, providing information on clinical course and 
prognosis, as well as guiding antimicrobial stewardship (10). 
Procalcitonin (PCT)
Although the clinical significance of measuring PCT, the 
116-amino-acid precursor of the active hormone calcitonin, 
is now virtually undisputed for diagnosing and managing 
bacterial sepsis (11), controversial evidence has been 
provided on its diagnostic value in patients with invasive 
fungal infections. More specifically, the low diagnostic 
sensitivity and specificity of this biomarker seemingly 
represent the largest barriers for its routine use in this 
clinical setting (12,13). Important supporting evidence on 
the questionable value of PCT in fungal sepsis emerged 
from the publication of some recent studies. Nath et al 
Table 1 Diagnostic features of laboratory tests for screening or diagnosing invasive fungal infections
Diagnostic features
Microscopic 
examination
Blood culture
Serological 
testing
1,3-beta-D-glucan, mannan antigen 
and anti-mannan antibodies
Molecular biology Presepsin
Diagnostic accuracy Modest/high Modest/high Modest Modest/high Modest/high High
Etiological diagnosis Modest High High No High No
Risk of environmental 
contamination
Modest High No No High No
False negative results 
with antifungal agents
Low High Low Low Modest Low
Availability in all clinical 
laboratories
Modest Modest Modest/high Modest Modest High
Rapidity High Low Modest/high Low Modest High
Throughput Low Low Modest/high Low Modest/high Modest
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measured PCT in 300 pediatric oncology patients with 
suspected bloodstream infections (14), and found that 
the values were considerably higher in those with Gram-
negative infection (n=28; 19.1 ng/mL) than in those with 
Gram-positive (n=11; 0.54 ng/mL) or Candida (n=4; 
0.32 ng/mL) infections. Pieralli et al. measured PCT in 
64 patients with Candida sepsis and in 128 with bacterial 
sepsis (15), reporting that values were significantly higher 
in those with bacterial sepsis [median, 4.48; interquartile 
range (IQR), 1.10–18.26 ng/mL] than in those with Candida 
sepsis (median, 0.73; IQR, 0.26–1.85 ng/mL; P<0.001). 
Notably, the AUC of PCT for distinguishing Gram-
negative bacteria from fungal infections was as high as 0.94 
(95% CI, 0.92–0.97). Finally, Thomas-Rüddel et al. studied 
4,858 sepsis patients treated in intensive care unit (16). 
Overall, PCT concentration was found to be considerably 
higher in patients with Gram-negative bacterial sepsis 
(n=720; median, 26 ng/mL; IQR, 7.7–63.1 ng/mL) than in 
those with Gram-positive bacterial sepsis (n=855; median, 
7.1 ng/mL; IQR, 2.0–23.3 ng/mL) or Candida sepsis 
(n=68; median, 4.7 ng/mL; IQR, 1.9–13.7 ng/mL) (both 
P<0.001). PCT displayed a good diagnostic efficiency 
for distinguishing patients with Gram-negative bacterial 
sepsis from those with Gram-positive bacterial sepsis or 
Candida sepsis (AUC, 0.69; 95% CI, 0.67–0.72). According 
to the cumulative findings of these three recent studies, 
the standardized mean difference of PCT values between 
patients with Gram-negative bacterial sepsis (n=876) and 
fungal sepsis (n=136) was 19.9 ng/mL (95% CI, 18.6–21.2; 
P<0.001), which means that PCT values were nearly 90% 
lower in the former category of patients compared to those 
with invasive fungal infection.
Presepsin
Presepsin, which is also known as soluble CD14 subtype 
(sCD14-ST), is a glycoprotein fragment mostly produced 
by macrophages or monocytes in response to infections (17). 
Presepsin can now be measured with immunochemistry 
techniques, which allow obtaining the first results in nearly 
20–30 min after sample collection (the measuring time 
is ~15 min), especially when using point-of-care (POC) 
devices. The kinetics of presepsin is extraordinarily rapid 
in blood; the concentration increases within 2 hours 
after the onset of bacterial or fungal infections, the peak 
concentration is then reached between 2–4 hours, and the 
half-life is typically comprised between 4–6 hours (17).
The potential usefulness of measuring presepsin in sepsis 
diagnostics has only recently emerged (i.e., the first study 
appeared ~15 years ago) (18), whilst the evidence that serum 
PCT concentrations are increased in patients with infections 
and sepsis was published in The Lancet by Assicot et al., 
in 1993 (19), anticipated by earlier studies demonstrating 
that elevated values of calcitonin-related peptides are 
commonplace during severe infections (20,21). This relative 
delay is then reflected by the considerable discrepancy in 
the overall number of studies which have so far assessed 
“procalcitonin” AND “sepsis” (source PubMed, n=2,021) 
or “presepsin” AND “sepsis” (source PubMed, n=140). 
Although it is hence conceivable that the predictably larger 
diffusion of presepsin immunoassays would assist filling this 
gap, two important studies have recently contributed to 
provide interesting insights on the use of this biomarker for 
diagnosing invasive fungal infections.
Bamba et al. studied 11 consecutive patients with fungal 
sepsis, in whom they measured the concentration of both 
PCT and presepsin (22). Interestingly, although PCT values 
were only found to be elevated (i.e., >0.5 ng/mL) in 5/11 
patients (diagnostic accuracy, 0.45; 95% CI, 0.17–0.77), two 
of whom with concomitant bacterial infection, presepsin 
level was found to be higher than the diagnostic cut-off (i.e., 
>500 pg/mL) in 10/11 patients (diagnostic accuracy, 0.90; 
95% CI, 0.59–1.00). In the six patients with sepsis, PCT 
and presepsin values were found to be increased over the 
diagnostic threshold in 4/6 (diagnostic accuracy, 0.67; 95% 
CI, 0.22–0.96) and 6/6 (diagnostic accuracy, 1.00) patients, 
respectively. The concentration of both biomarkers was 
found to be correlated with the sequential organ failure 
assessment (SOFA) score, though the correlation was higher 
for presepsin (r=0.89; P<0.001) than for PCT (r=0.64; 
P=0.034).
Another interesting experimental study was published 
by Bazhenov et al. (23), who studied presepsin expression 
in peripheral blood mononuclear cells of 19 healthy 
volunteers, which were challenged with Candida albicans 
lysate, lipopolysaccharide or autologous serum. Notably, 
24 hours after the in vitro challenge, the concentration 
of presepsin in the supernatant was 59.8 pg/mL (range, 
29.7–140 pg/mL) in cells treated with lipopolysaccharide, 
84 pg/mL (range, 38.8–133 pg/mL) in those treated 
with Candida albicans lysate and 34.6 pg/mL (range, 
18.5–81.8 pg/mL) in those challenged with autologous 
serum, respectively. A similar trend was noted after 
48 hours, with presepsin concentration in the supernatant 
of cells challenged with Candida albicans lysate remaining 
1.3-fold and 2.8-fold higher than in the supernatant of cells 
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challenged with lipopolysaccharide or autologous serum, 
respectively. Overall, the concentration of presepsin in the 
supernatant was significantly higher after challenge with 
Candida albicans lysate than with lipopolysaccharide (P<0.05) 
or autologous serum (P<0.001).
Conclusions
According to the Third International Consensus Definitions 
for Sepsis and Septic Shock (Sepsis-3), sepsis is currently 
defined as a “life-threatening organ dysfunction caused by 
dysregulated host response to infection” (24). This updated 
definition underscores the clinical importance of the “non-
homeostatic” host response to an infection rather than 
the infection per se, so that the concepts of “bacteraemia”, 
“fungemia” and even of “bloodstream infection” shall be 
no longer used as synonyms for sepsis. The first obvious 
consequence is that the measurement of biomarkers which 
essentially reflect a disproportionate “non-homeostatic” 
host response would appear more efficient for initial 
screening of patients with sepsis compared to the direct 
isolation or identification of microorganisms from blood. 
In fact, a systemic biological response, up to systemic 
inflammatory response syndrome (SIRS) and multi organ 
failure, can also occur in patients with severe but localized 
infections, even before microorganisms have massively 
entered the bloodstream (Figure 1).
The preliminary albeit intriguing findings of the two 
studies investigating the role of presepsin in invasive fungal 
infections (22,23), along with some notable technical 
advantages (Table 1), conceivably pave the way to developing 
algorithms based on results of both PCT and presepsin 
testing (measured in combination for screening and 
differential diagnosis of patients with sepsis), which should 
then be validated in real life scenarios. Concomitantly 
increased values of PCT and presepsin would thus appear 
suggestive of bacterial sepsis (especially Gram-negative 
bacterial sepsis) or mixed infection, non-diagnostic values 
of both biomarkers may enable to safely rule out sepsis of 
both bacterial or fungal origin, whilst a disproportionate 
increase of presepsin values combined with normal or only 
modestly elevated PCT concentration would be suggestive 
for invasive fungal infection. Additional tests, such as those 
reported in Table 1, can then be planned for achieving a 
more accurate etiological diagnosis (Figure 1). 
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